Afghani Behnoosh, Ngo Thienkim, Leu Szu-Yun, Wu Fu L, Cecilio Maricel, Aron-Johnson Pamela, Zeitany Raja, Sills Jack, Amin Alpesh
Department of Pediatrics, University of California, Irvine, CA, USA.
Pediatr Infect Dis J. 2006 Nov;25(11):1019-24. doi: 10.1097/01.inf.0000243164.47048.4b.
To determine the effect of an interventional program designed to improve adherence to American Academy of Pediatrics (AAP) guidelines for palivizumab prophylaxis.
The study was carried out at the Children's Hospital, University of California, Irvine Medical Center and its affiliated clinics. An interventional program focusing on education of health care workers on AAP guidelines, updating health care providers about respiratory syncytial virus (RSV) activity, as well as designating a single clinic with effective screening of referrals for administration of palivizumab, was implemented during the summer of 2004. The medical records of infants who had received at least 1 dose of palivizumab or were eligible to receive palivizumab during the 2003-2004 and the 2004-2005 RSV seasons at the University of California, Irvine Medical Center were reviewed. The proportion of patients who received injections according to AAP guidelines was compared.
After the intervention, the proportion of patients who received palivizumab injections according to AAP recommendations increased from 39% to 61% (P < 0.0001). The program decreased the proportion of unnecessary injections significantly (140/525, or 27%, in 2003-2004 to 33/323, or 10%, in 2004-2005; P < 0.0001) but did not change the proportion of missing injections. The program resulted in a significant drop (14% to 2%; P < 0.0001) in proportion of palivizumab injections that were given too late, when RSV activity had subsided. RSV hospitalization rates did not change as a result of the intervention.
Our interventional program improved adherence to AAP guidelines mainly by decreasing the unnecessary palivizumab injections.
确定一项旨在提高对美国儿科学会(AAP)帕利珠单抗预防指南依从性的干预项目的效果。
该研究在加利福尼亚大学欧文医学中心儿童医院及其附属诊所进行。2004年夏季实施了一项干预项目,重点是对医护人员进行AAP指南教育、向医疗服务提供者通报呼吸道合胞病毒(RSV)活动情况,以及指定一家诊所对转诊患者进行有效筛查以给予帕利珠单抗。回顾了在加利福尼亚大学欧文医学中心2003 - 2004年和2004 - 2005年RSV流行季节期间接受过至少1剂帕利珠单抗或有资格接受帕利珠单抗的婴儿的病历。比较了按照AAP指南接受注射的患者比例。
干预后,按照AAP建议接受帕利珠单抗注射的患者比例从39%增至61%(P < 0.0001)。该项目显著降低了不必要注射的比例(从2003 - 2004年的140/525,即27%,降至2004 - 2005年的33/323,即10%;P < 0.0001),但未改变漏注的比例。该项目使在RSV活动消退后才注射帕利珠单抗的比例显著下降(从14%降至2%;P < 0.0001)。干预后RSV住院率未发生变化。
我们的干预项目主要通过减少不必要的帕利珠单抗注射提高了对AAP指南的依从性。